Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tegileridine + propofol
- Development stage
- Phase 4
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Tegileridine + propofol is an intravenous anesthetic combination consisting of tegileridine, a novel μ-opioid receptor (MOR) agonist, and propofol, a sedative-hypnotic agent. Tegileridine (SHR8554) is a biased ligand designed to provide potent analgesia while potentially minimizing opioid-related adverse effects such as respiratory depression and gastrointestinal dysfunction by selectively activating the G-protein signaling pathway over the β-arrestin-2 pathway. Propofol functions as a positive allosteric modulator of the GABA_A receptor, inducing rapid sedation and hypnosis. This combination is primarily investigated for the induction of general anesthesia, specifically to inhibit airway responses during laryngeal mask airway (LMA) insertion and to maintain hemodynamic stability in both young and elderly patients.
- Other names
- SHR8554 + propofol
02
Targets
DOR (Opioid Receptor Delta 1)GABA-B (Gamma-aminobutyric acid receptor type B)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)
Beyond the preview
Go deeper on tegileridine + propofol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tegileridine + propofol.